Amcare Healthcare is a technology company.
Amcare Healthcare has raised $17.0M across 1 funding round.
Amcare Healthcare has raised $17.0M in total across 1 funding round.
Amcare Healthcare (also known as Beijing Amcare Women’s & Children’s Hospital) is a leading private healthcare provider in China specializing in obstetrics, gynecology, pediatrics, and postpartum care. It operates a network of seven women's and children's hospitals, two integrated clinics, and five postpartum centers across major cities like Beijing and Shenzhen, delivering high-quality services through advanced medical technologies, AI integration, and an internationally recognized management system.[2][4][5][6]
The company serves mothers, infants, and families, addressing critical needs in maternal and child health—such as premium obstetrics, in-vitro fertilization (obtained via a 2020 hospital acquisition), and education on infant nutrition via programs like "The First 1,000 Days."[2][6] It solves gaps in China's private healthcare by combining personalized care with tech-driven efficiency, employing 50-99 staff and generating $1-5M in revenue, with growth fueled by a 2022 acquisition by ByteDance (TikTok's parent) for ~10 billion yuan, enhancing its digital health capabilities amid a booming $89B online health sector.[4][6]
Founded in 2006 in Beijing, China, Amcare emerged as a premium brand in the private obstetrics and gynecology-pediatrics sector, initially focusing on high-quality maternal and child services.[2][5][6] Its backstory ties to addressing rising demand for specialized women's and children's care in a market dominated by public hospitals, quickly expanding to a national network while earning investor backing from firms like Warburg Pincus, Hillhouse Capital, and China Renaissance.[2][6]
A pivotal moment came in 2020 with a government license for in-vitro fertilization through a Beijing hospital acquisition, broadening its offerings.[6] Early traction included sponsorships like the multi-year "The First 1,000 Days" program with China's Ministry of Civil Affairs and National Health Commission, educating families on early infant nutrition.[2] In 2022, ByteDance acquired full ownership, marking one of China's largest tech-health deals post-regulatory crackdowns and integrating Amcare into its Xiaohe health app ecosystem.[6]
Amcare rides China's digital health wave, where tech giants like ByteDance, Alibaba, and Ping An are disrupting traditional care via apps for consultations, bookings, and wellness in an $89B sector accelerated by pandemic measures.[6] Its 2022 ByteDance acquisition—valued at ~10B yuan—exemplifies tech firms entering healthcare amid regulatory shifts curbing "disorderly expansion," positioning Amcare to blend physical hospitals with online services like those of its parent company's Xiaohe app.[6]
Market forces favoring Amcare include urbanization-driven demand for premium maternal-child care, IVF liberalization, and tech adoption in a population-focused nation.[6] It influences the ecosystem by modeling hybrid tech-health models, inspiring similar investments and elevating private providers' role in national health goals like infant welfare programs.[2]
With ByteDance's resources, Amcare is poised to expand its hospital network and deepen AI-driven services, potentially integrating TikTok-like engagement for health education and Xiaohe for seamless virtual-physical care.[6] Trends like AI personalization, online health growth, and policy support for private IVF will shape its path, amid competition from Alibaba Health and Ping An.[6]
Its influence may evolve from niche premium provider to a scalable tech-health leader, amplifying ByteDance's diversification beyond social media—watch for new product launches or further M&A in women's health tech. This positions Amcare as a key player bridging China's healthcare gaps with innovative, patient-focused momentum.[2][4][6]
Amcare Healthcare has raised $17.0M in total across 1 funding round.
Amcare Healthcare has raised $17.0M across 1 funding round. Most recently, it raised $17.0M Series B in November 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2019 | $17.0M Series B |